internal medicine resident half day ahsan alam md n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Acute Renal Failure PowerPoint Presentation
Download Presentation
Acute Renal Failure

play fullscreen
1 / 76

Acute Renal Failure

173 Views Download Presentation
Download Presentation

Acute Renal Failure

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Internal Medicine Resident Half-Day Ahsan Alam, MD Acute Renal Failure

  2. Internal Medicine Resident Half-Day Ahsan Alam, MD AcuteKidneyInjury

  3. What is Acute Kidney Injury Abrupt decline in GFR Increase in serum creatinine PUF = (PGC - PT) - (pGC - pT) Varying definitions (RIFLE, AKIN, etc)

  4. Rising Prevalence of AKI

  5. Why do we care about AKI? Mortality with hospital-acquired AKI Mortality post cardiac surgery Nash K et al. Am J Kidney Dis 2002;39(5):930-936 Lassnigg, A. et al. J Am Soc Nephrol 2004;15:1597-1605

  6. Case #1 A 76 yr old female presents to ED with abdominal pain and dyspnea Serum creatinine is 135 mmol Does she have AKI?

  7. Diagnostic Approach Time of onset – prior serum creatinine Careful review of history and physical exam Comorbidities Medications Current illness (vomiting, diarrhea, blood loss, etc) BP, volume status, skin lesions, flank/abdominal signs

  8. Case #1 DM2, HTN, CAD (CABG 2004), CVA 2000 (right CEA 2009), hypothyroidism Medications telmistartan 80 mg, ramipril 10 mg, furosemide 40/80 mg, metoprolol, clonidine, atorvastatin, clopidogrel, insulin, thyroxine If this is AKI, what are the most likely diagnoses?

  9. Causes of Hospital-Acquired AKI and Mortality 4,622 consecutive patients 7.3% with AKI Nash K et al. Am J Kidney Dis 2002;39(5):930-936

  10. Case #1 The patient undergoes investigations for her symptoms in hospital…

  11. Case #1 *CI-AKI

  12. Case #1 *CI-AKI *Stage 2-3 AKI

  13. AKI Network (AKIN) Classification Lopes, J. A. et al. Crit Care 2008;12(4):R110

  14. Risk Factors for AKI Lameire et al. NDT. 2008;6:392

  15. Consistent Risk Factors • Age • Hypovolemia • Hypotension • Sepsis • CKD • Hepatic dysfunction • Cardiac dysfunction • DM • Exposure to nephrotoxins

  16. Differential Diagnosis of AKI Pre-renal Renal Post-renal

  17. Pre-renal Hypovolemia Diuretics, trauma, surgery, burns, hemorrhage, pancreatitis, GI loss, etc. Decreased effective circulating volume Nephrotic sydrome, cirrhosis, CHF, tamponade, massive PE, etc. Renovascular obstruction RAS/atherosclerosis/thrombosis/embolism, dissecting aneurysm, vasculitis, compression Impaired glomerular autoregulation NSAIDs, ACEi/ARB, calcineurin inhibitors

  18. Intrinsic Renal Glomerular and small vessel diseases Rapidly progressive GN, endocarditis, post-strep GN, vasculitides, scleroderma/malignant HTN, HUS, PET, DIC Interstitial nephritis Infection-related, inlammation, drug-induced, infiltrative (lymphoma, leukemia, sarcoidosis) Tubular Lesions Post-ishemia, nephrotoxic (drugs, contrast, anesthetics, heavy metals), pigment nephropathy, light chain, hypercalcemia

  19. Post-renal Bladder flow obstruction Urethral, bladder neck (BPH), neurogenic bladder Ureteral obstruction (bilateral or single kidney) Stones, clots, tumours, papillary necrosis, retroperitoneal fibrosis, surgical ligation

  20. Urine Output and AKI Anuric < 50 cc / 24 hrs Oliguric < 500 cc / 24 hrs Non-olguric Normal urine output, but inadequate clearance GFR 2 ml/min will produce ~3L of urine/day if there is no tubular reabsorption

  21. Diagnostic Approach Urine dipstick Urine microscopy Cellular elements RBC, WBC, Renal tubular epithelial cells Other (squamous, vaginal) Casts Hyaline, granular, waxy, RBC, WBC, tubular cell Organisms Bacteria, yeast Crystals Lipiduria Specific gravity pH Leukocytes Nitrites Protein Glucose Ketones Urobilinogen Bilirubin Blood

  22. Urine Findings WBC casts - pyelonephritis WBC

  23. Urine Findings Crystalluria – uric acid Crystalluria – calcium oxalate (ethylene glycol toxicity)

  24. Urine Findings RBC casts - GN Dysmorphic RBC - GN

  25. Urine Findings Muddy brown casts – acute tubular necrosis

  26. Urine Findings 1.030 Specific gravity pH 5.0 Leukocytes Nitrites Protein Glucose Ketones + Urobilinogen Bilirubin Blood ++++ 80 yo female found on the floor of her apartment after 2 days, SCr 400 mol/L, K 6.8 mmol/L, CK 54,000

  27. Urine Indices

  28. Urine Indices

  29. FeNa Limitations of FeNa Diuretic use Post-ischemic ATN who have less severe disease AKI on chronic pre-renal disease (cirrhosis, CHF) Contrast or pigment nephropathy Acute GN or vasculitis Alternatives FE of urea, lithium, uric acid FeNa = UNa/PNa x 100 UCr/PCr

  30. Imaging Assess kidney size/morphology Hydronephrosis

  31. Kidney Biopsy Intrinsic renal AKI Indications Isolated glomerular hematuria with proteinuria Nephrotic syndrome Acute nephritic syndrome Unexplained acute or rapidly progressive AKI

  32. Kidney Biopsy Crescentic GN

  33. Principles of AKI Management • Identify AKI • Avoid further nephrotoxic injury • Optimize renal hemodynamics • Treat complications • Fluid balance, electrolytes, uremia • Nutritional support • Renal Support (RRT) • Monitoring after AKI

  34. Medications • Pre-renal • Calcineurin inhibitors, radiocontrast, ACEi/ ARB, NSAIDS, amphotericin B • Intra-renal • aminoglycosides, amphotericin B, cisplatin, cephalosporins, sulfa, rifampin, NSAIDS, interferon • Post-renal • acyclovir, MTX, indinavir, sulfadiazine • Review renal dosing of medications

  35. Fluid Management • Correct fluid deficit • Will not guarantee AKI prevention • Studies of PA catheters did not reduce AKI • High urine flow in specific conditions • Myoglobinuria, tumour lysis, contrast media, etc. • Little evidence on fluid choice • Crystalloids • Hypooncotic colloids (4% albumin) • Hyperoncotic solutions (HES, dextrans) carry risk of renal dysfunction

  36. Renal Perfusion and Vasoactive Agents • No support for • Loop diuretics • Dopamine • Selected use of • Mannitol (Rhabdomyolysis, post-cardiac surgery) • Unclear support for • Natriuretic peptides (ANP, BNP) • Fenoldopam (DA agonist) • Theophylline (adenosine antagonist)

  37. Renal Perfusion • Vasopressors • Inotropes to improve low cardiac function • Target MAP needs to be individualized • Commonly 65 mmHg • Higher in elderly where autoregulation impaired

  38. Nutrition in AKI • AKI is a catabolic state • Inadequate nutritional support can delay renal recovery • Cochrane review 2010: • “There is not enough evidence to support the effectiveness of nutritional support for AKI…” • Adequate calorie delivery in anuric patient will necessitate RRT

  39. Treat Complications • Monitor and correct electrolytes, acidosis • Renal replacement therapy • If indicated, do not withhold until patient is anuric

  40. Indications for Dialysis A E I O U Acidosis Electrolyte disturbance Ingestions Overload (volume) Uremia

  41. New Paradigm for AKI CKD AKD AKI

  42. Natural history of AKI Cerda et al. cJASN. 2008;

  43. Follow up after AKI

  44. Questions?

  45. Case #1 *CI-AKI *Stage 2-3 AKI

  46. Fluids – Isotonic vs. Hypotonic Isotonic saline (0.9%) more protective than half normal (0.45%) 1,620 pts undergoing cardiac catheterization Goal is to achieve ‘good’ urine flow Mueller C et al. Arch Intern Med. 162: 329-336, 2002

  47. Fluids Optimal rate and duration is not clear IV rate >1-1.5 ml/kg/hr to achieve urine flow >150 ml/hr At least 1hr (3-12hr) prior and 3-6hr (6-12hr) after contrast

  48. Bicarbonate vs Saline Zoungas S et al. Ann Intern Med 2009;151:631-638

  49. Bicarbonate vs Saline Zoungas S et al. Ann Intern Med 2009;151:631-638